Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations [0.03%]
EGFR和MAPK共突变患者中有利于免疫的微环境
Wang Yang,Naifei Chen,Lingyu Li et al.
Wang Yang et al.
Purpose: Although EGFR-mutated patients generally do not benefit from checkpoint inhibitors (ICIs), some patients in the KEYNOTE-001 study consistently benefited from this treatment. This study investigated immune microen...
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer [0.03%]
派姆单抗单药治疗非小细胞肺癌患者时免疫相关不良事件与疗效的关系研究
Susumu Noguchi,Keiichiro Suminaga,Takahiro Kaki et al.
Susumu Noguchi et al.
Purpose: The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed dea...
Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature [0.03%]
依维莫司在肺神经内分泌肿瘤治疗中的临床评估：患者选择及特殊考虑。系统的文献批判性回顾
Marta Peri,Nicola Fazio
Marta Peri
Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last dec...
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors [0.03%]
携带ALK基因内部倒位或缺失重排的非小细胞肺癌患者的ROS1激酶抑制剂治疗反应持久
Alexa B Schrock,Russell Madison,Mark Rosenzweig et al.
Alexa B Schrock et al.
Background: ALK fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring ALK rearrangements without a fusion partner identified in DNA have also been shown to respond to...
Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin [0.03%]
用于小细胞肺癌治疗的在研孤儿药Lurbinectedin的新进展
Diego Kauffmann-Guerrero,Rudolf Maria Huber
Diego Kauffmann-Guerrero
Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatmen...
Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients [0.03%]
ROS1重排非小细胞肺癌在印度的发病情况及克唑替尼治疗肺腺癌患者的疗效
Anurag Mehta,Mumtaz Saifi,Ullas Batra et al.
Anurag Mehta et al.
Background: The ROS1 gene is a member of the "sevenless" subfamily of tyrosine-kinase insulin-receptor genes. ROS1-fusion rearrangement causes constitutive downstream signal transduction, with an oncogenic role in non-sma...
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives [0.03%]
不可切除III期非小细胞肺癌免疫检查点抑制剂治疗新进展及展望
Hiroyuki Inoue,Isamu Okamoto
Hiroyuki Inoue
There has been no improvement in outcome for patients with unresectable locally advanced (stage III) non-small cell lung cancer (NSCLC) for more than 10 years. The standard treatment for these patients is definitive concurrent chemotherapy ...
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases [0.03%]
洛拉替尼治疗ALK重排型NSCLC患者引起的需要神经外科手术的放射性脑病：两例报告
Viola W Zhu,Misako Nagasaka,Takafumi Kubota et al.
Viola W Zhu et al.
Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). Next-generation ALK tyrosine kinase inhibitors (TKIs) are highly CNS-pe...
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer [0.03%]
当前关于石棉引起肺癌的表观遗传学改变的研究理解
Yuen Yee Cheng,Emma M Rath,Anthony Linton et al.
Yuen Yee Cheng et al.
Asbestos is a naturally occurring mineral consisting of extremely fine fibres that can become trapped in the lungs after inhalation. Occupational and environmental exposures to asbestos are linked to development of lung cancer and malignant...
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies [0.03%]
克唑替尼治疗后使用艾乐替尼患者的阳性非小细胞肺癌（NSCLC）的NP28673和NP28761二期研究中的反应持续时间
Shirish Gadgeel,Alice T Shaw,Fabrice Barlesi et al.
Shirish Gadgeel et al.
Introduction: Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American ...